Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Cadranel

Showing results (251-260 of 329) with videos related to

Pageof 33
Sort By:
Scientific Reports|June 10, 2022
Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patientsGuillaume Voiriot, Karim Dorgham, Guillaume Bachelot, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
ERJ Open Research|February 3, 2021
The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensusArgyris Tzouvelekis, Katerina Antoniou, Michael Kreuter, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 30, 2026
Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experienceJelena Filipovic, Emma Anjorand, Laetitia Marisa, et al.
Respirology (Carlton, Vic.)|March 18, 2024
Chronic interstitial lung disease associated with systemic lupus erythematosus: A multicentric study of 89 casesLou Deneuville, Arthur Mageau, Marie Pierre Debray, et al.
The European Respiratory Journal|September 19, 2015
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504Jacques Cadranel, Radj Gervais, Patrick Merle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC studyThomas Pierret, Laurent Greillier, Florian Guisier, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.
The Oncologist|August 28, 2020
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case SeriesJacques Cadranel, Stephen V Liu, Michaël Duruisseaux, et al.
Pageof 33

Showing results (251-260 of 329) with videos related to

Sort By:
Pageof 33
Scientific Reports|June 10, 2022
Identification of bronchoalveolar and blood immune-inflammatory biomarker signature associated with poor 28-day outcome in critically ill COVID-19 patientsGuillaume Voiriot, Karim Dorgham, Guillaume Bachelot, et al.
ERJ Open Research|February 17, 2018
Real-life experience of ceritinib in crizotinib-pretreated <i>ALK</i><sup>+</sup> advanced non-small cell lung cancer patientsJacques Cadranel, Alexis B Cortot, Hervé Lena, et al.
ERJ Open Research|February 3, 2021
The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey: international survey and call for consensusArgyris Tzouvelekis, Katerina Antoniou, Michael Kreuter, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 30, 2026
Integrative and interactive genomic analyses guiding personalized combined therapy improve clinical benefit in metastatic patients: A monocentric real-life experienceJelena Filipovic, Emma Anjorand, Laetitia Marisa, et al.
Respirology (Carlton, Vic.)|March 18, 2024
Chronic interstitial lung disease associated with systemic lupus erythematosus: A multicentric study of 89 casesLou Deneuville, Arthur Mageau, Marie Pierre Debray, et al.
The European Respiratory Journal|September 19, 2015
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504Jacques Cadranel, Radj Gervais, Patrick Merle, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 13, 2019
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm studySimon Baldacci, Martin Figeac, Martine Antoine, et al.
Lung Cancer (Amsterdam, Netherlands)|October 3, 2025
Real-world efficacy and safety of amivantamab in EGFR exon-20-mutant non-small cell lung cancer in a French early-access program: Amexon 20 GFPC studyThomas Pierret, Laurent Greillier, Florian Guisier, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.
The Oncologist|August 28, 2020
Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case SeriesJacques Cadranel, Stephen V Liu, Michaël Duruisseaux, et al.
Pageof 33